Amycretin (Zenagamtide): When It Will Be Available and Trial Results

When will amycretin be available?

Novo Nordisk said in June 2025 that it would move both the shot and the pill into phase 3 for weight management ^[4]. Its August 2026 report says the AMAZE phase 3 program started in the first half of 2026, that AMAZE 8, a trial against semaglutide, is expected to read out in the first half of 2029, and that a heart failure outcomes trial, HF-POLARIS, is expected to read out in the second half of 2029 ^[1]. A phase 3 start for the pill was listed for the third quarter of 2026 ^[1].

Novo has not said when it will file with FDA. FDA review of a complete application takes 6 to 10 months ^[5]. On Novo's stated trial dates, approval is years away. Track it in our GLP-1 pipeline tracker. Amgen's MariTide and Boehringer Ingelheim's survodutide have pages too.

Amycretin trial results

No phase 3 results have been reported. The numbers below come from two earlier trials of the weekly shot. The obesity figures assume everyone kept to their dosing schedule.

Average weight change in amycretin trials of the weekly shot

Trial	Who was in it	Dose and time point	Amycretin	Placebo	Source
Phase 1b/2a	125 adults with overweight or obesity	1.25 mg, 20 weeks	-9.7%	+1.9%	[2]
Phase 1b/2a	125 adults with overweight or obesity	5 mg, 28 weeks	-16.2%	+2.3%	[2]
Phase 1b/2a	125 adults with overweight or obesity	20 mg, 36 weeks	-22.0%	+2.0%	[2]
Phase 2	262 adults with type 2 diabetes	40 mg, 36 weeks	Up to -14.6%	-2.1%	[3]

In the type 2 diabetes trial, A1C fell by up to 1.71 points from a starting average of 7.8%, and Novo saw no plateau in weight loss at 36 weeks on the higher doses ^[3]. Novo plans a phase 3 program in type 2 diabetes starting in the second half of 2026 ^[3].

Amycretin side effects

In both trials, Novo said the most common side effects were stomach-related and mostly mild to moderate, consistent with other incretin and amylin drugs ^{[2] [3]}. Novo has not published side effect rates for phase 3 yet.

How amycretin works

Amycretin is one molecule that acts on two receptors: GLP-1, like Wegovy, and amylin, a hormone released with insulin ^[3]. Novo's other amylin drug, CagriSema, takes a different route: it is two separate drugs, cagrilintide and semaglutide, in one shot ^[6]. Novo is testing amycretin both as a weekly shot and as a pill ^[4]. For background, see how GLP-1 drugs work.

Amycretin vs Wegovy and Zepbound

No head-to-head result exists yet; AMAZE 8 will compare amycretin with semaglutide ^[1]. The table shows each drug's main trial for context. Amycretin's numbers come from a small, short early trial, so they cannot be compared fairly with the large phase 3 trials of approved drugs.

Amycretin, Wegovy and Zepbound: status and main trial results

	Amycretin	Wegovy (semaglutide)	Zepbound (tirzepatide)
FDA status	Phase 3, not approved [1]	Approved	Approved
Receptors	GLP-1 and amylin [3]	GLP-1	GIP and GLP-1 [7]
Main trial reported	Phase 1b/2a, 125 adults, 36 weeks [2]	STEP 1, 68 weeks [8]	SURMOUNT-1, 72 weeks [9]
Average weight change	-22.0% on 20 mg vs +2.0% [2]	-14.9% on 2.4 mg vs -2.4% [8]	-20.9% on 15 mg vs -3.1% [9]
Self-pay price a month	None	$199 to $399, NovoCare, checked Oct 17, 2026 [10]	$299 to $449, LillyDirect, checked Oct 17, 2026 [11]

See Wegovy vs Zepbound, Wegovy cost and Zepbound cost.

How to get amycretin legally

Only in a clinical trial. Search open studies under both names, amycretin and zenagamtide, on ClinicalTrials.gov. It is not approved, so no pharmacy can fill it. FDA warns that unapproved GLP-1 products sold online have unknown quality and may be harmful ^[12]. See research-use-only GLP-1s and approved options in online GLP-1 programs.

How we check

Status, results and timelines come from Novo Nordisk's own releases and its SEC filing. When Novo reports phase 3 results or files with FDA, this page and the pipeline tracker change.